Maleno Isabel, Cabrera Carmen Maria, Cabrera Teresa, Paco Laura, López-Nevot Miguel Angel, Collado Antonia, Ferrón Antonio, Garrido Federico
Servicio de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014 Granada, Spain.
Immunogenetics. 2004 Jul;56(4):244-53. doi: 10.1007/s00251-004-0692-z. Epub 2004 Jul 16.
HLA class I loss or down-regulation is a widespread mechanism used by tumor cells to avoid tumor recognition by cytotoxic T lymphocytes, and thus favor tumor immune escape. Multiple mechanisms are responsible for these HLA class I alterations. In different epithelial tumors, loss of heterozygosity (LOH) at chromosome region 6p21.3, leading to HLA haplotype loss, occurs in 6-50% of all cases depending on the tumor entity. In this paper we report the frequency of LOH at 6p21 in 95 colorectal carcinomas (CRC) previously analyzed for altered HLA class I expression with immunohistological techniques. We used PCR microsatellite amplification of selected STR markers located on Chromosome 6 to identify LOH with DNA from microdissected tumor tissues and the surrounding stroma. Sequence-specific oligonucleotide analysis was performed in microdissected stroma and tumor cells for HLA typing, and to detect HLA haplotype loss. A high frequency (40%) of HLA haplotype loss was found in CRC. Eight tumors showed microsatellite instability. We sometimes observed two or more mechanisms responsible for HLA alteration within the same HLA-altered phenotype, such as LOH and HLA class I total loss. In 25 tumors (26%) no HLA class I alteration could be identified. These data are potentially relevant for CRC patients undergoing T-cell-based immunotherapy.
HLA I类分子缺失或下调是肿瘤细胞用于逃避细胞毒性T淋巴细胞对肿瘤的识别从而促进肿瘤免疫逃逸的一种广泛机制。多种机制导致了这些HLA I类分子的改变。在不同的上皮性肿瘤中,6号染色体区域6p21.3的杂合性缺失(LOH)导致HLA单倍型丢失,在所有病例中的发生率为6%至50%,具体取决于肿瘤类型。在本文中,我们报告了95例先前用免疫组织学技术分析过HLA I类分子表达改变的结直肠癌(CRC)中6p21处LOH的频率。我们使用位于6号染色体上的选定STR标记进行PCR微卫星扩增,以从显微切割的肿瘤组织和周围基质的DNA中鉴定LOH。对显微切割的基质和肿瘤细胞进行序列特异性寡核苷酸分析以进行HLA分型,并检测HLA单倍型丢失。在结直肠癌中发现了高频(40%)的HLA单倍型丢失。8个肿瘤显示微卫星不稳定。我们有时在同一HLA改变的表型中观察到两种或更多种导致HLA改变的机制,如LOH和HLA I类分子完全丢失。在25个肿瘤(26%)中未发现HLA I类分子改变。这些数据对于接受基于T细胞的免疫治疗的结直肠癌患者可能具有相关性。